- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, November 8, 2019
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
A study published in the 2019 September issue of The American Journal of Managed Care® (AJMC®) examined UnitedHealthcare’s Institutional Special Needs Plans and their association with hospital and skilled nursing facility use. The study, “Managed Care for Long-Stay Nursing Home Residents: An Evaluation of Institutional Special Needs Plans,” was highlighted in an article by Skilled Nursing News.
OBR Daily’s featured oncology news of Thursday, November 7, included an article from AJMC®’s sister site The Center for Biosimilars® titled “First Rituximab Biosimilar, Truxima, Launches in the United States.” The article highlighted the launch of Teva and Celltrion’s biosimilar rituximab, Truxima, which is being offered at a 10% discount to the list price of the reference product, Rituxan.
Next Avenue’s article on the use of telehealth for effective psychotherapy at home referenced a study from the January 2019 issue of AJMC®, titled “Patient and Clinician Experiences With Telehealth for Patient Follow-up Care,” which highlighted the convenience and efficacy of telemedicine.
An article posted on AAMC.org that described treatments available for migraine relief highlighted a 2018 study summary from AJMC® titled “Study Summary: Costs Associated With Migraine in the United States.” The study dicsussed the rising costs in migraine care and the need to curb these costs to limit productivity losses and economic burdens.
A coverage with evidence development (CED) study demonstrated significant and clinically meaningful benefits in patients with migraine treated with remote electrical neuromodulation (REN). Health plans should support clinicians’ REN prescriptions by ensuring adequate coverage.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen
